Poxel SA: Poxel Reports Financial Results for First Half 2021 and Provides a Corporate Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Key Factors Signal Infection Risk in Alcoholic Hepatitis medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Look Beyond Liver Biopsy for NAFLD Diagnosis medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021
with product launch anticipated in 2021
1
Poxel regained Imeglimin rights from Metavant for US, Europe and other countries not covered by its agreement with Sumitomo Dainippon Pharma and is pursuing next steps to advance its development including partnering activities
Poxel continues to prepare for initiation of Phase 2b trial with PXL770 in patients with biopsy-proven NASH and pre-diabetes or type 2 diabetes, expected to commence in H2 2021
PXL065 Phase 2 study ongoing with completion of recruitment expected in mid-2021 and topline data readout in mid-2022
Imeglimin and PXL065 preclinical and clinical data published in peer reviewed journals; PXL770 data accepted for oral and poster presentations at an upcoming scientific conference